AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10719658 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational psychotherapy
Number of subjects: 106
Study 10719658 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 106
Study 8651472 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 1% (Tilarin), QID, 1 spray per nostril
Number of subjects: 166
Study 8651472 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 1% (Tilarin), QID
Number of subjects: 166
Study 8651472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 1640161 — intervention group
Group type: EXPERIMENTAL
Intervention: Attribution retraining
Number of subjects: 29
Study 1640161 — intervention group
Group type: COMPARATOR
Intervention: Neutral feedback
Number of subjects: 29
Study 6424997 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion, 100 mg by mouth three times a day for 9 days
Number of subjects: 8
Study 6424997 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine, 25 mg by mouth three times a day for 9 days
Number of subjects: 8
Study 6424997 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion, 25 mg/kg subcutaneously for 16 days
Number of subjects: 8
Study 6424997 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine, 5 mg/kg subcutaneously for 16 days
Number of subjects: 8
Study 31516127 — intervention group
Group type: EXPERIMENTAL
Intervention: Medisafe app (intervention group)
Number of subjects: 51
Study 31516127 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 51
Study 29579345 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic formula (PF, n = 60)
Number of subjects: 180
Study 29579345 — intervention group
Group type: COMPARATOR
Intervention: Regular formula (RF, n = 60)
Number of subjects: 180
Study 29579345 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic formula (PF)
Number of subjects: 180
Study 29579345 — intervention group
Group type: COMPARATOR
Intervention: Breastfed (BF)
Number of subjects: 180
Study 29579345 — intervention group
Group type: COMPARATOR
Intervention: Regular formula (RF)
Number of subjects: 180
Study 26643793 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training and home‐based rehabilitation program plus educational‐behavioral therapy
Number of subjects: 46
Study 26643793 — intervention group
Group type: COMPARATOR
Intervention: Educational‐behavioral therapy alone
Number of subjects: 46
Study 25509727 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at qijie area combined with spine balance-regulating massage
Number of subjects: 100
Study 25509727 — intervention group
Group type: COMPARATOR
Intervention: Medication group (oral nimodipine 30 mg three times a day and vinpocetine injection with glucose or saline)
Number of subjects: 100
Study 23043451 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine L-alpha-ketoglutarate, methylsulfonylmethane, hydrolyzed type I collagen and bromelain (Group I)
Number of subjects: 90
Study 23043451 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (Group II - no supplement)
Number of subjects: 90
Study 20372900 — intervention group
Group type: EXPERIMENTAL
Intervention: Low central venous pressure (LCVP) technique, CVP maintained below 5 mmHg or 40% lower than baseline during the preanhepatic phase.
Number of subjects: 86
Study 20372900 — intervention group
Group type: EXPERIMENTAL
Intervention: Low central venous pressure (LCVP) technique
Number of subjects: 86
Study 20372900 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 86
Study 17509164 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin/pemetrexed followed by docetaxel (AP-Doc)
Number of subjects: 178
Study 17509164 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin/cyclophosphamide followed by docetaxel (AC-Doc)
Number of subjects: 178
Study 15650645 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg every 8 hours for 7 days)
Number of subjects: 8
Study 15650645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12085384 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance with correction of stenosis before thrombosis
Number of subjects: 0
Study 12085384 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow determination as surveillance method
Number of subjects: 0
Study 12085384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound dilution for blood flow measurements
Number of subjects: 0
Study 12085384 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance programs
Number of subjects: 0
Study 10613424 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture solution (L‐arginine hydrochloride 100 mg x kg(‐1) + L‐ornithine hydrochloride 80 mg x kg(‐1) + L‐branched chain amino acids 140 mg x kg(‐1))
Number of subjects: 10
Study 10613424 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P1‐AS)
Number of subjects: 10
Study 10613424 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture solution (AS)
Number of subjects: 10
Study 7598296 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusions
Number of subjects: 29
Study 2193123 — intervention group
Group type: EXPERIMENTAL
Intervention: Nipple stimulation (NS)
Number of subjects: 0
Study 350501 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% dithranol in a 17% urea base (Psoradrate)
Number of subjects: 8
Study 350501 — intervention group
Group type: COMPARATOR
Intervention: Base alone (17% urea)
Number of subjects: 8
Study 30698299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of amygdalin at 0.6 mg/kg bw
Number of subjects: 60
Study 30698299 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of amygdalin at 3.0 mg/kg bw
Number of subjects: 60
Study 30698299 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of crushed bitter apricot seeds at 60 mg/kg bw
Number of subjects: 60
Study 30698299 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of crushed bitter apricot seeds at 300 mg/kg bw
Number of subjects: 60
Study 30698299 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amygdalin)
Number of subjects: 60
Study 30233114 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated yoga therapy module practices, 1 h/day, 5 days a week for 6 weeks
Number of subjects: 88
Study 30233114 — intervention group
Group type: COMPARATOR
Intervention: Physical exercises for 1 h/day, 5 days a week for 6 weeks
Number of subjects: 88
Study 26755201 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy (LPP)
Number of subjects: 326
Study 26755201 — intervention group
Group type: COMPARATOR
Intervention: Short-term psychodynamic psychotherapy (SPP)
Number of subjects: 326
Study 26755201 — intervention group
Group type: COMPARATOR
Intervention: Solution-focused therapy (SFT)
Number of subjects: 326
Study 25440797 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-based intervention package (education tools to enhance self-care and adherence, and regular follow-up by the CHW)
Number of subjects: 806
Study 25440797 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 806
Study 21425210 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental Formula (EF)
Number of subjects: 34
Study 21425210 — intervention group
Group type: COMPARATOR
Intervention: Polymeric Formula (PF)
Number of subjects: 34
Study 21425210 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EF and PF
Number of subjects: 34
Study 21144356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic video-otoendoscopic examination (VOE)
Number of subjects: 29
Study 21144356 — intervention group
Group type: COMPARATOR
Intervention: Still examination group (control)
Number of subjects: 29
Study 17394891 — intervention group
Group type: EXPERIMENTAL
Intervention: Self etching priming agent (Xeno III)
Number of subjects: 60
Study 17394891 — intervention group
Group type: COMPARATOR
Intervention: Traditional acid etch and Prime and Bond
Number of subjects: 60
Study 17167134 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated vaccine
Number of subjects: 1247
Study 17167134 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated vaccine
Number of subjects: 1247
Study 12868045 — intervention group
Group type: EXPERIMENTAL
Intervention: AAS self-administration for 8 weeks
Number of subjects: 48
Study 12868045 — intervention group
Group type: EXPERIMENTAL
Intervention: AAS self-administration for 12-16 weeks
Number of subjects: 48
Study 12868045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (200 mg/wk i.m.) for 8 weeks
Number of subjects: 48
Study 12868045 — intervention group
Group type: EXPERIMENTAL
Intervention: AAS administration regimen and length of abuse
Number of subjects: 48
Study 12868045 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic evaluation
Number of subjects: 48
Study 10360909 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical evacuation using misoprostol
Number of subjects: 635
Study 10360909 — intervention group
Group type: COMPARATOR
Intervention: Surgical evacuation
Number of subjects: 635
Study 7491378 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine plus lithium [CBZ‐Li]
Number of subjects: 33
Study 7491378 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol plus lithium [HAL‐Li]
Number of subjects: 33
Study 1772727 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous suture including a stitch in the fascia
Number of subjects: 35
Study 1772727 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous suture not including a stitch in the fascia
Number of subjects: 35
Study 6175340 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon arc laser photocoagulation
Number of subjects: 0
Study 6175340 — intervention group
Group type: COMPARATOR
Intervention: Argon laser photocoagulation
Number of subjects: 0
Study 6175340 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral retinal ablation (argon and xenon groups)
Number of subjects: 0
Study 6175340 — intervention group
Group type: EXPERIMENTAL
Intervention: Panphotocoagulation (argon and xenon groups)
Number of subjects: 0
Study 29901422 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial cerebrospinal fluid (ACF) irrigation
Number of subjects: 342
Study 29901422 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) irrigation
Number of subjects: 342
Study 29901422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ACF and NS groups
Number of subjects: 342
Study 28627976 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium administered based on fat-free mass
Number of subjects: 60
Study 28627976 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium administered based on real body weight
Number of subjects: 60
Study 25862360 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding stents (SES) with distal embolic protection devices (EPD)
Number of subjects: 127
Study 25862360 — intervention group
Group type: COMPARATOR
Intervention: Balloon-expandable stents (BES) without EPD
Number of subjects: 127
Study 24059911 — intervention group
Group type: COMPARATOR
Intervention: Quinine + clindamycin
Number of subjects: 0
Study 24059911 — intervention group
Group type: COMPARATOR
Intervention: Alternative artemisinin-based combination therapy
Number of subjects: 0
Study 24059911 — intervention group
Group type: EXPERIMENTAL
Intervention: Same first-line artemisinin-based combination therapy
Number of subjects: 0
Study 20801439 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist inducing a hypogonadic state during IVF-ET cycles
Number of subjects: 108
Study 20801439 — intervention group
Group type: COMPARATOR
Intervention: Controlled ovarian stimulation protocols
Number of subjects: 108
Study 19694927 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Udenafil
Number of subjects: 165
Study 19694927 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Udenafil
Number of subjects: 165
Study 19694927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 17426277 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg rHA0 vaccine (15 microg H1, 45 microg H3)
Number of subjects: 460
Study 17426277 — intervention group
Group type: EXPERIMENTAL
Intervention: 135 microg rHA0 vaccine (45 microg each of H1, H3, B)
Number of subjects: 460
Study 17426277 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 460
Study 15285978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 10502022 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 72
Study 10502022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 8886414 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg TAK-044
Number of subjects: 0
Study 8886414 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg TAK-044
Number of subjects: 0
Study 8886414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1860682 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III supplementation (3,000 units before hemodialysis)
Number of subjects: 24
Study 1860682 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III supplementation
Number of subjects: 24
Study 1860682 — intervention group
Group type: COMPARATOR
Intervention: Control (no antithrombin III supplementation)
Number of subjects: 24
Study 6849754 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 0
Study 6849754 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (80 mg)
Number of subjects: 0
Study 6849754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31769635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 723
Study 31769635 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 723
Study 31769635 — intervention group
Group type: EXPERIMENTAL
Intervention: Both positions
Number of subjects: 723
Study 29600887 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolichoectasia
Number of subjects: 1089
Study 29600887 — intervention group
Group type: COMPARATOR
Intervention: No dolichoectasia
Number of subjects: 1089
Study 26137496 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful awareness practices (MAP), 8 weekly sessions
Number of subjects: 29
Study 26137496 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 29
Study 22664804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler systolic indices
Number of subjects: 100
Study 22664804 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain (S) and Strain Rate (SR) imaging
Number of subjects: 100
Study 20857772 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic chair massage and patient teaching in diaphragmatic breathing
Number of subjects: 0
Study 18578173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultreo toothbrush used according to manufacturer's instructions for 2 minutes
Number of subjects: 31
Study 18578173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultreo toothbrush (power turned off) used like a manual toothbrush for 2 minutes
Number of subjects: 31
Study 18578173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultreo toothbrush held approximately 3 mm from tooth surfaces for 2 minutes by a dental hygienist
Number of subjects: 31
Study 18578173 — intervention group
Group type: COMPARATOR
Intervention: Swishing with a dentifrice slurry for 1 minute
Number of subjects: 31
Study 15786890 — intervention group
Group type: EXPERIMENTAL
Intervention: 2RZ (rifampicin plus pyrazinamide)
Number of subjects: 352
Study 15786890 — intervention group
Group type: COMPARATOR
Intervention: 6H (isoniazid)
Number of subjects: 352
Study 12407127 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg twice a day for 7 days
Number of subjects: 12
Study 12407127 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav 1000 mg once a day for 7 days
Number of subjects: 12
Study 10499899 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous coronary perfusion with warm blood enriched with esmolol
Number of subjects: 60
Study 10499899 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia
Number of subjects: 60
Study 8711052 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Rational-Emotive Behavior Therapy (9 weekly sessions)
Number of subjects: 44
Study 8711052 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group (no intervention during control period)
Number of subjects: 44
Study 1748109 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA) supplement during the race
Number of subjects: 2
Study 1748109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 1748109 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA) supplement during the marathon
Number of subjects: 2
Study 6130291 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice daily for two years
Number of subjects: 1285
Study 6130291 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 1285
Study 6130291 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1285
Study 30352443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-Mini PCNL (UMP)
Number of subjects: 180
Study 30352443 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Ureteroscopy (FURS)
Number of subjects: 180
Study 30352443 — intervention group
Group type: COMPARATOR
Intervention: Shock Wave Lithotripsy (SWL)
Number of subjects: 180
Study 30395021 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (5-minute duration, three times per day for 6 weeks)
Number of subjects: 28
Study 30395021 — intervention group
Group type: COMPARATOR
Intervention: Control (no acupressure intervention)
Number of subjects: 28
Study 30395021 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 28
Study 30395021 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 27333088 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC) 150 mg
Number of subjects: 262
Study 27333088 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 262
Study 27333088 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with moderate neuropsychological impairment at baseline
Number of subjects: 262
Study 24563240 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning (e-CAMS)
Number of subjects: 215
Study 24563240 — intervention group
Group type: EXPERIMENTAL
Intervention: in-person CAMS training
Number of subjects: 215
Study 24563240 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 215
Study 22332800 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day MMI
Number of subjects: 449
Study 22332800 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day MMI
Number of subjects: 449
Study 22332800 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day PTU
Number of subjects: 449
Study 22332800 — intervention group
Group type: COMPARATOR
Intervention: MMI to PTU switch
Number of subjects: 449
Study 19787388 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb remote ischemic preconditioning (RIPC) induced twice (24 h and 1 h preoperatively) via three 5‐min cycles of ischemia and reperfusion on the left upper arm using a blood pressure cuff.
Number of subjects: 60
Study 19787388 — intervention group
Group type: EXPERIMENTAL
Intervention: Limb remote ischemic preconditioning (RIPC)
Number of subjects: 60
Study 19787388 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 17520260 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud-bath treatment (12 mud packs and thermal baths)
Number of subjects: 80
Study 17520260 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mud-bath treatment)
Number of subjects: 80
Study 17956712 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronic acid 4 mg
Number of subjects: 422
Study 17956712 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 422
Study 15238233 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich diet
Number of subjects: 90
Study 15238233 — intervention group
Group type: COMPARATOR
Intervention: Normal iso-caloric diet
Number of subjects: 90
Study 15238233 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented diet (green tea and soy products)
Number of subjects: 90
Study 11082825 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch
Number of subjects: 108
Study 11082825 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 108
Study 9349604 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 400 mg twice daily for 2 weeks
Number of subjects: 20
Study 9349604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1347231 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.08 mg kg‐1 or 0.10 mg kg‐1
Number of subjects: 40
Study 1347231 — intervention group
Group type: COMPARATOR
Intervention: Atracurium 0.4 mg kg‐1 or 0.5 mg kg‐1
Number of subjects: 40
Study 4016938 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 72
Study 4016938 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen
Number of subjects: 72
Study 30531191 — intervention group
Group type: COMPARATOR
Intervention: AGV revision
Number of subjects: 41
Study 30531191 — intervention group
Group type: EXPERIMENTAL
Intervention: Visco-Trabeculotomy (VT)
Number of subjects: 41
Study 29472491 — intervention group
Group type: COMPARATOR
Intervention: Monthly sulfadoxine‐pyrimethamine and 2 doses of azithromycin (AZI‐SP)
Number of subjects: 1320
Study 29472491 — intervention group
Group type: COMPARATOR
Intervention: Control (2 doses of sulfadoxine‐pyrimethamine)
Number of subjects: 1320
Study 29472491 — intervention group
Group type: COMPARATOR
Intervention: Monthly sulfadoxine‐pyrimethamine
Number of subjects: 1320
Study 26899387 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 μg calcitriol orally twice a day for 3 days prior to surgery
Number of subjects: 0
Study 26899387 — intervention group
Group type: COMPARATOR
Intervention: Selective vitamin D treatment for patients with postoperative hypocalcaemia (control)
Number of subjects: 0